tiprankstipranks
Japan Medical Dynamic Marketing, Inc. (JP:7600)
:7600
Japanese Market

Japan Medical Dynamic Marketing, Inc. (7600) AI Stock Analysis

Compare
0 Followers

Top Page

JP:7600

Japan Medical Dynamic Marketing, Inc.

(7600)

Select Model
Select Model
Select Model
Neutral 63 (OpenAI - 5.2)
Rating:63Neutral
Price Target:
¥573.00
▲(17.66% Upside)
Action:ReiteratedDate:03/14/26
The score is driven primarily by moderate financial strength: a solid balance sheet is offset by 2025 profitability deterioration and negative free cash flow. Technical signals are mixed-to-weak (below the 20-day average, softer momentum), while valuation is a relative support with a reasonable P/E and dividend yield.
Positive Factors
Strong balance sheet
A strong equity base and healthy equity ratio provide financial resilience against shocks and discretionary flexibility for R&D, certifications, or targeted investments. Over a 2-6 month horizon this stability reduces refinancing risk and supports execution while profitability recovers.
Negative Factors
Negative net profit in 2025
A negative net margin indicates the company reported operating losses that erode retained earnings and could force strategic trade-offs. Persisting losses over several quarters would reduce reinvestment ability, pressure stakeholder confidence, and may necessitate restructuring or external funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong balance sheet
A strong equity base and healthy equity ratio provide financial resilience against shocks and discretionary flexibility for R&D, certifications, or targeted investments. Over a 2-6 month horizon this stability reduces refinancing risk and supports execution while profitability recovers.
Read all positive factors

Japan Medical Dynamic Marketing, Inc. (7600) vs. iShares MSCI Japan ETF (EWJ)

Japan Medical Dynamic Marketing, Inc. Business Overview & Revenue Model

Company Description
Japan Medical Dynamic Marketing, INC. develops, manufactures, imports, and sells medical devices in Japan and the United States. The company provides trauma devices, including nails, screws, plates, and other products surgically implanted in the f...
How the Company Makes Money
null...

Japan Medical Dynamic Marketing, Inc. Financial Statement Overview

Summary
Stable revenue growth and a strong, low-leverage balance sheet support the score, but profitability weakened with negative net income in 2025 and free cash flow turned negative, raising execution and liquidity concerns.
Income Statement
65
Positive
Balance Sheet
72
Positive
Cash Flow
60
Neutral
BreakdownTTMMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue24.98B25.11B23.18B21.31B19.19B16.74B
Gross Profit14.46B15.65B14.76B13.99B12.99B11.42B
EBITDA1.03B1.40B3.27B3.35B4.21B3.47B
Net Income-669.47M-461.80M1.27B1.42B2.14B1.66B
Balance Sheet
Total Assets32.22B33.83B31.49B29.43B27.34B25.19B
Cash, Cash Equivalents and Short-Term Investments2.35B3.18B2.32B2.80B2.59B2.47B
Total Debt4.31B3.29B1.49B1.87B1.85B3.09B
Total Liabilities8.25B9.09B5.88B6.14B5.85B6.48B
Stockholders Equity23.96B24.68B25.51B23.16B21.39B18.63B
Cash Flow
Free Cash Flow0.00-504.10M302.45M870.67M1.53B1.23B
Operating Cash Flow0.001.05B2.10B2.19B3.11B2.60B
Investing Cash Flow0.00-1.67B-1.80B-1.48B-1.75B-1.35B
Financing Cash Flow0.001.49B-840.71M-514.78M-1.29B-1.31B

Japan Medical Dynamic Marketing, Inc. Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price487.00
Price Trends
50DMA
542.62
Negative
100DMA
514.91
Positive
200DMA
524.49
Positive
Market Momentum
MACD
-4.45
Positive
RSI
43.57
Neutral
STOCH
13.91
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7600, the sentiment is Neutral. The current price of 487 is below the 20-day moving average (MA) of 601.60, below the 50-day MA of 542.62, and below the 200-day MA of 524.49, indicating a neutral trend. The MACD of -4.45 indicates Positive momentum. The RSI at 43.57 is Neutral, neither overbought nor oversold. The STOCH value of 13.91 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:7600.

Japan Medical Dynamic Marketing, Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
78
Outperform
¥20.32B15.123.02%-4.36%-14.92%
68
Neutral
¥97.03B26.702.31%4.36%79.43%
65
Neutral
¥252.17B36.371.92%4.31%96.31%
63
Neutral
¥15.20B14.763.12%3.59%-163.08%
56
Neutral
¥65.24B87.82-0.46%-4.30%82.87%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
51
Neutral
¥142.06B28.052.42%3.73%0.04%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:7600
Japan Medical Dynamic Marketing, Inc.
577.00
-25.67
-4.26%
JP:7779
CYBERDYNE
309.00
125.00
67.93%
JP:6523
PHC Holdings Corp.
1,121.00
90.80
8.81%
JP:4549
Eiken Chemical Co., Ltd.
2,943.00
647.24
28.19%
JP:6678
Techno Medica Co., Ltd.
2,384.00
636.48
36.42%
JP:6849
Nihon Kohden Corporation
1,510.50
-514.19
-25.40%

Japan Medical Dynamic Marketing, Inc. Corporate Events

Japan Medical Dynamic Marketing Profit Slumps but Dividend Raised Despite Weak Outlook
Jan 30, 2026
Japan Medical Dynamic Marketing reported a 2.9% year-on-year decline in net sales to ¥17.9 billion for the nine months ended December 31, 2025, with operating profit dropping 57.9% to ¥518 million and profit attributable to owners of par...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Mar 14, 2026